Relaxera

Relaxera is a clinical-stage biotechnology company headquartered in Bensheim, Germany, dedicated to the development of recombinant human Relaxin-2 (rhRLX) for the treatment of severe cardiovascular and fibrotic diseases. The company was founded by Prof. Dr. Wolf-Georg Forssmann, a pioneer in peptide research who discovered several circulating hormones. Relaxera's primary focus is on the pleiotropic effects of Relaxin-2, which include vasodilation, anti-fibrotic activity, and organ protection. Their clinical programs target indications such as systemic sclerosis (scleroderma), liver cirrhosis, and acute heart failure. By leveraging the natural biological properties of the relaxin peptide, Relaxera aims to provide transformative therapies for patients with limited treatment options. The company maintains a strong intellectual property portfolio surrounding the therapeutic use and production of relaxin-like peptides.